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ABSTRACT 
Introduction: The decision as to the most appropriate site of care of a patient with 
community-acquired pneumonia (CAP), especially whether hospitalisation is 
warranted or not, is one of the most important decisions in the overall emergency 
department management of such patients. It has consequences both with regard to 
the level of treatment received by the patient as well as the overall costs of 
treatment. Several tools have been developed to predict mortality and/or determine 
which patients could be sent home and treated safely with good clinical outcomes. 
The CRB-65 score is one of the validated severity of illness scoring tools 
recommended. This scoring system may be of particular benefit in resource-
constrained areas, as it is easier to use. 
Study’s aim: To determine whether it would be useful to introduce the CRB-65 
severity of illness score in the routine evaluation of patients with CAP in the Helen 
Joseph Hospital Emergency Department (HJH ED). 
Study’s objectives: To determine what criteria HJH ED doctors use in their 
decision to admit or discharge CAP patients; to determine the frequency with which 
the CRB-65 severity of illness score is used in current practice by the HJH ED 
doctors for admitting or discharging CAP patients; and to determine the potential 
performance of the CRB-65 severity of illness score in the management of patients 
with CAP in the HJH ED. 
Design: Prospective, observational, hospital-based study. 
Setting: Emergency Department of the Helen Joseph Hospital.  
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Patients and methods: All patients 18 years of age and older with the diagnosis 
of CAP constituted our study population. Data from 152 patients seen between 
February 2011 and April 2011 was collected and analysed. Outcome measures 
included hospital admission or discharge, time to clinical stability, length of hospital 
stay, and mortality. 
Results: Overall, 152 patients (79 females and 73 males) were included in the 
analysis. The median age was 36.5 years, with a range from 20 to 87 years. The 
chest radiograph was the commonest criterion (41%) used by the HJH ED doctors to 
determine the need for admission of the patients with CAP, while the haemodynamic 
parameters were the commonest criteria used (25.9%) for discharge decisions. On 
only three occasions was the CRB-65 score utilised out of the 193 criteria 
documented (1.55%). 
There was a significantly shorter time to clinical stability (p = 0.0069), but no 
tendency to a shorter length of hospital stay in patients with a lower CRB-65 score (p 
= 0.5694). Patients with a higher CRB-65 score were at significantly higher risk of 
death compared to patients with a lower CRB-65 score (p < 0.001). There were no 
deaths from outpatients, but there were a total of five deaths observed from the in-
hospital patients of which 3/5 patients (60%) would potentially have been classified 
as intermediate mortality risk and the remaining 2/5 patients (40%) as high mortality 
risk if the CRB-65 score had been the only criterion used as the standard for site of 
care decisions by the HJH ED doctors. 
Conclusion: The chest radiograph was the commonest criterion used by the HJH 
ED doctors to determine the need for admission of the patients with CAP, while the 
haemodynamic parameters were the commonest criteria used for discharge 
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decision. The CRB-65 score is not frequently being used in current practice by the 
HJH ED doctors for admitting or discharging CAP patients. 
This study demonstrates the ability of the CRB-65 severity of illness score to 
accurately predict both the time to clinical stability for patients hospitalised with CAP 
and the risk of death associated. In addition, this study documents that the CRB-65 
severity of illness score performed well in its ability to determine the initial site of care 
for patients with CAP. 
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CHAP 1. COMMUNITY-ACQUIRED PNEUMONIA: 
LITERATURE REVIEW 
1.1. Background information 
Despite recent advances in the management of the disease, community-acquired 
pneumonia (CAP) is still a common and potentially lethal infectious disease. In the 
USA, it is estimated that 4 to 5 million cases occur annually, accounting for 
approximately 10 million physician visits, 500 000 hospitalisations, 45 000 deaths 
(the sixth leading cause of death), and an annual cost of $23 billion.1  
In the RSA, 20% of all deaths in children under five years of age are due to acute 
lower respiratory infections, and 90% of these deaths are due to pneumonia.2 It 
became the fifth-largest cause of mortality in the country in 2000, accounting for 
3.9% of all deaths.3 A recent South African study reported a 20% mortality rate for 
adult patients hospitalised with CAP.4   
CAP mortality is variable, depending on the site of care: it is less than 1% in the 
outpatient setting,5,6 around 5–15% in inpatients not requiring ICU care, up to 25% in 
intubated patients, and nearly 50% in ICU patients requiring vasopressors.5,7,8 In the 
assessment and management of patients with CAP, determination of disease 
severity is crucial, since it guides various therapeutic options such as the site of care 
(i.e. need for hospital or ICU admission or suitability for home care), the extent of the 
microbiological investigation, and the choice and route of empiric antimicrobial 
chemotherapy. Inpatient treatment of pneumonia is approximately 25 times more 
expensive per patient than outpatient treatment.7 
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The decision as to the most appropriate site of care of a patient with CAP, especially 
whether hospitalisation is warranted or not, is one of the most important decisions in 
the overall emergency department (ED) management of such patients. It has 
consequences both with regard to the level of treatment received by the patient as 
well as the overall costs of treatment. Such decisions are best informed by an 
accurate assessment of the severity of illness of the patient at the time of 
presentation.  
Several tools have been developed to predict mortality and/or assist in determining 
which patients could be sent home and treated safely with good clinical outcomes. 
The CURB-65 score (Figure 1.1) is one of the two most extensively studied and 
validated severity of illness scoring tools. It was derived from the British Thoracic 
Society rule, is simple to use, and its accuracy is similar to that of the more 
complicated scoring systems, such as the Pneumonia Severity Index (Table 1.1).5,9 
Five risk classes are derived from the CURB-65 score, with different predicted 
mortalities. Class 0 has a predicted mortality of approximately 0.7%, class 1, 2.1%, 
class 2, 9.2%, class 3, 14.5%, and class 4, 40-57%. Patients in classes 0 and 1 are 
at low risk of mortality and may be suitable for outpatient treatment. Patients in class 
2 are at intermediate risk of mortality and should be considered for inpatient 
treatment. Patients in classes 3 and 5 are at higher risk of mortality and correspond 
to those who may need high care or ICU admission.5,10 For the PSI, five risk classes 
are derived with class I to III considered as low risk of mortality (0.1 to 2.8%), class 
IV as intermediate risk of mortality (8.2%), and class V as higher risk of mortality 
(29.2%). It is suggested that patients in classes I to III may be managed as hospital 
outpatients, patients in class IV need inpatient treatment, and patients in class V may 
need ICU care (Appendix A).5,10   
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A more simplified tool, the CRB-65 score was subsequently reported and studied 
(Table 1.1), in which the measurement of the only laboratory value of the CURB-65 
score, namely the blood urea nitrogen, was not required.9 This scoring system may 
be of particular benefit in resource-constrained areas, since it obviates the need to 
measure the blood urea level.  
Table 1.1: PSI score, CURB-65 score and CRB-65 hospital admission risk class 
stratification scores.5 
 
Risk class 
 
I II III IV V 
PSI score 
 
Points 
 
(A) < 70 71-90 91-130 > 130 
Mortality 
 
0.10% 0.60% 2.80% 8.20% 29.20% 
Site of care recommended 
 Out Out Out/b.I Inpatient Inpatient 
 
CURB-65 
Risk class 
 
0 1 2 3 4 
Mortality 
 
0.70% 2.10% 9.20% 14.50% 40-57% 
Score 
Site of care recommended 
 Out Out Inpatient Inpatient Inpatient 
 
CRB-65 
Risk class 
 
0 1 2 3 to 4 
 
Mortality 
 
1.20% 5.30% 12% 33% 
 
Score 
Site of care recommended 
 Out Inpatient Inpatient Inpatient 
 (A) risk class I: age < 50 years, no comorbidities, and absence of vital sign abnormalities. Out: outpatient. Out/b.I: 
outpatient or brief inpatient 
1.2. Severity of illness assessment of patients with CAP presenting 
to an emergency department (ED) 
Severity of illness assessment of patients with CAP presenting to an ED impacts on 
decisions regarding the site of care, the extensiveness of the microbiological and 
laboratory evaluation, the type, route, and duration of antibiotic therapy, the intensity 
of clinical observation and the overall medical resource use for this condition. 
Accurate prognostication helps to predict the expected outcomes and the probability 
of serious adverse events in the initial management decisions.  
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However, clinicians tend to overestimate the risk of death associated with CAP 
patients. This leads to unnecessary admissions to hospitals, as demonstrated in one 
of the biggest studies, in which 65.1% of low mortality risk patients were treated as 
inpatients.10,11 
1.3. Definition 
The term community-acquired pneumonia refers to pneumonia acquired within the 
general community and is defined as an acute infection (of less than 14 days 
duration) associated with inflammation of the lung parenchyma distal to the terminal 
bronchioles, most commonly bacterial in nature, and associated with clinical and/or 
radiological evidence of consolidation of part or parts of one or both lungs.9,12 
1.4. Aetiology 
The microbial aetiology of CAP varies widely according to the different reviews 
published. It is influenced by the geographic area, the population studied, and the 
diagnostic methods used.13 The causative pathogen remains unknown in some 30% 
to 60% of cases, despite vigorous clinical and laboratory investigations.1 
The organisms commonly associated with CAP include so-called “typical 
pathogens”, including Streptococcus pneumoniae, Haemophilus influenzae, 
Staphylococcus aureus, and Klebsiella pneumoniae, respiratory viruses including 
Influenza virus, respiratory syncitial virus, adenovirus, and parainfluenza virus and 
so-called "atypical pathogens" including Mycoplasma pneumoniae, Chlamydia 
pneumoniae, and Legionella species.1,9,13 This has led some to classify CAP as 
"CAP", "viral CAP" and "atypical CAP" respectively.1 
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The frequency of detection of the different pathogens, as causes of CAP, ranges 
between 20% to 60% for Streptococcus pneumoniae, 3% to 10% for Haemophilus 
influenzae, 1% to 6% for Mycoplasma pneumoniae, 3% to 5% for gram-negative 
bacilli and around 4% for Chlamydia pneumoniae, 2% to 8% for Legionella species, 
3% for Staphylococcus aureus, and 2% for viruses.1 Aspiration and other identified 
causes account for 6% to 10% and 10% to 40% respectively.1 
1.5. Pathophysiology of CAP14 
The lung offers a large epithelial surface (70 m2) that is exposed to the environment. 
This surface is constantly exposed to a multitude of potential pathogens. Pathogens 
can reach the lung by one of several routes, including haematogenous spread from 
distant foci, by inhalation of airborne pathogens, or most commonly by micro-
aspiration of microorganisms harboured in the nasopharynx.  
The organisms that more commonly reach the lungs through blood circulation are 
Staphylococcus spp; and gram-negative bacilli. The viruses reach the lungs through 
airborne droplets inhaled through the mouth and nose. Fungal pneumonia is rarely 
seen in the immune-competent host, and the mechanism of invasion is very similar 
to that of bacterial pneumonia.  
1.5.1. Host defence mechanisms15 
The respiratory tract has a multilayered defence mechanism to contain and eliminate 
these bacteria. A breach of these defences at any level will make an individual more 
prone to infection of the respiratory tract, including CAP. 
Mechanisms of host defence may be non-immunological or immunological. 
Immunological mechanisms may be natural (innate) or specific (humoral). 
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1.5.1.1. Non-immunological mechanisms 
Non-immunological mechanisms that protect against CAP include filtration of air as it 
passes through the nasopharynx, the glottal reflex, laryngeal closure, the cough 
reflex, clearance of organisms from the lower airways by ciliated cells and the 
mucociliary escalator, and ingestion of small bacterial inoculates that manage to 
reach alveolar spaces by pulmonary macrophages and PMNs. 
1.5.1.2. Immunological mechanisms 
1.5.1.2.1. Innate immunity 
Innate immune mechanisms participate in clearance of pneumococci from the 
nasopharynx, as well in phagocytosis by PMNs and macrophages via the microbial 
pattern recognition receptor, Toll-like receptor 2. 
1.5.1.2.2. Humoral immunity 
Immunologically specific humoral mechanisms provide the best protection against 
host invasion by microorganisms. These include activation and production of 
cytokines, toxin neutralisation, complement activation, and opsonin promotion. The 
antibody response to infection, typically involving the development of Ig M during the 
initial acute infection followed by Ig G, is one of the most important pathogen-specific 
responses and plays an important role in diagnostic evaluation. 
 
 
 
7 
 
1.5.2. Pathogenesis 
Once the microorganism is able to evade or overcome all of these defences, it can 
flourish in the alveolus, start to multiply and to release damaging toxins that cause 
inflammation and oedema of the lung parenchyma, leading to accumulation of 
cellular debris and exudates within the lungs.14,16 
Exudation of protein fluid in alveolar spaces is associated with ventilation-perfusion 
impairment, and decrease in lung compliance, contributing to increased work of 
breathing and hypoxia. The inflammatory process is orchestrated by pro-
inflammatory cytokines such as tumour necrosis factors and the interleukin (IL) 
series (IL-1, IL-2, IL-6, and IL-8), and is balanced by anti-inflammatory mediators. 
Cytokines are largely responsible for the clinical and laboratory manifestations of 
bacterial CAP.17 
In most acute bacterial pneumonias, the major mechanism for arterial hypoxaemia is 
intrapulmonary shunt caused by maintenance of pulmonary arterial blood flow to the 
consolidated lung, leading to a ventilation–perfusion mismatch.17 There is also 
evidence that metabolically active inflammatory cells within the consolidated lung 
consume oxygen, thus further decreasing pulmonary venous oxygen content and 
arterial oxygenation.17 
1.6. Complications of CAP18,19 
Complications of CAP include pleural effusion, empyema or pyothorax, lung 
abscess, secondary bacterial lung infection after a viral infection, sepsis, respiratory 
failure, acute respiratory distress syndrome, haemoptysis, atelectasis, 
bronchospasm, and death. 
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1.7. Diagnosis of CAP 
1.7.1. Clinical presentation 
CAP can vary from indolent to fulminant in presentation and from mild to fatal in 
severity. The various signs and symptoms, which depend on the progression and 
severity of the infection, include both constitutional effects and manifestations limited 
to the lung and its associated structures. In the light of the pathophysiology of the 
disease, many of the findings are to be expected.  
The patient is frequently febrile, with a tachycardia, and may have chills and/or 
sweats and cough, either non-productive or productive of mucoid, purulent, or blood-
tinged sputum, pleuritic chest pain or chest discomfort, palpitations, and shortness of 
breath. Up to 20% of patients may have gastrointestinal symptoms such as nausea, 
vomiting, and/or diarrhoea and abdominal pain. Other symptoms may include 
headaches, fatigue or malaise, anorexia, myalgias, and arthralgias.16 
Findings on physical examination vary with the degree of pulmonary consolidation 
and the presence or absence of a significant pleural effusion. An increase in 
respiratory rate and use of accessory muscles of respiration are common. Palpation 
may reveal increased or decreased tactile fremitus, and the percussion note can 
vary from dull to stony dull, reflecting underlying consolidated lung and pleural fluid, 
respectively. Crackles, bronchial breath sounds, and possibly a pleural friction rub 
and signs of bronchial secretions (rhonchi and wheezing) may be heard on 
auscultation.16 The clinical presentation may not be as obvious in the elderly, who 
may display new-onset or worsening confusion and few other manifestations.16 
Symptoms and signs of conditions complicating CAP may be present as well.  
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Unfortunately, the sensitivity and specificity of the findings on physical examination 
are less than ideal, averaging 58% and 67%, respectively.17 Furthermore, the overall 
prevalence of CAP among unselected patients presenting with respiratory 
complaints ranges from about 3% to 10%, depending on the setting. There are no 
individual (or combination of) findings on the history, physical examination, or 
laboratory examination that can rule in or out the diagnosis of CAP with adequate 
accuracy.19 Therefore, the diagnosis of CAP relies both on the presence of 
symptoms and signs of acute pulmonary infection and on evidence of a new 
radiographic infiltrate.19 
1.7.2. Risk factors for CAP 
Risk factors associated with any type of CAP are race (black), alcoholism, drug 
abuse, tobacco smoking, prior antibiotic use, steroid therapy, advanced age, recent 
travel history, associated comorbidities such as immunosuppression, asthma, 
COPD, stroke, diabetes, heart failure, seizures, renal failure, liver failure and 
dementia.17 
1.7.3. Chest radiograph 
With a sensitivity of 65%-85% and specificity of 85%-95%, a chest radiograph (CXR) 
is usually regarded as the reference standard for the diagnosis of CAP.13,19 In the 
appropriate setting, a new area of consolidation on CXR makes the diagnosis.9,20 
Occasionally, the CXR initially appears normal, particularly in immunocompromised 
and in severely dehydrated patients.19,20 
The CXR may show lobar consolidation, involving single or, less commonly, multiple 
lobes with air-bronchograms, as the most common pattern of presentation of 
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pneumococcal CAP, reticular or reticulonodular in pattern associated with interstitial 
CAP resulting from atypical pathogen and viral infections, or bronchopneumonic 
changes with peribronchial thickening and poorly defined air-space opacities with no, 
or inhomogeneous, patchy areas of consolidation that usually involve several 
lobes.13 The radiological pattern is unhelpful in suggesting likely aetiology, because 
the changes are not specific enough with the different microorganisms to be of 
diagnostic value. 
A CXR is advisable in all patients who are likely to have pneumonia, because it helps 
to confirm the diagnosis, delineate the extent of the consolidation, indicate the 
presence of underlying disorders, and denote the presence of complications.9,21  
1.7.4. Laboratory studies 
1.7.4.1. Sputum microscopy and culture 
There is debate about the value of sputum samples in the diagnosis of CAP. Oral 
flora rather than the offending pathogen may dominate a sputum Gram’s stain and 
culture. The guidelines provided by the IDSA recommend pathogen-directed therapy 
assisted by Gram’s stain (and culture) even though acknowledging that the yield of 
positive results is low (30% to 40%).22 The guidelines of the ATS are less supportive 
of the Gram’s stain, stating that due to the low yield and low specificity, empiric 
therapy to cover all likely organisms is preferred.22 Nevertheless, most experts 
believe that an attempt should be made to obtain a sputum sample before 
commencing antibiotic therapy, as this is sometimes the best opportunity to identify 
pathogens that may need special attention.23  
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Unfortunately the routine use of sputum Gram’s stain as a basis for empiric therapy 
in the ED can be problematic for several reasons. Firstly, many patients are not able 
to provide adequate sputum specimens. Secondly, induction of sputum without 
adequate isolation facilities can put patients and staff at risk of being infected with 
microorganism such as tuberculosis. Thirdly, correlation between pneumococcus 
identification on Gram’s stain and sputum culture and the presence or absence of 
pneumococcal infection is poor. Fourthly, sputum specimens are even less likely to 
demonstrate gram-negative pathogens, such as Haemophilus influenzae. Lastly, 
empiric antimicrobial agents are usually highly clinically effective, if chosen on the 
basis of clinical information, and they do not require sputum analysis.6 
1.7.4.2. Blood culture 
Blood cultures are the most specific diagnostic test for the causative organism, but 
are positive in only around 10% of patients admitted to hospital with CAP; the more 
severe the pneumonia, the more likely blood cultures are to be positive.23  
Most experts recommend that blood be cultured from all patients, except those well 
enough to be managed at home with oral antibiotics, and should be obtained before 
initiation of antimicrobial therapy.22,23 
1.7.4.3. Blood chemistry and haematology24 
A number of investigations are recommended. On a white blood cell and differential 
count, leukocytosis or left shift may be seen and leucopoenia has been linked to a 
poor prognosis. Abnormal renal or liver function tests have been associated with 
CAP, and have implications for medication. C-reactive protein (CRP) as a septic 
marker is usually elevated. Serum glucose is recommended to exclude any hypo- or 
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hyperglycaemia, and lactate to exclude any tissue hypoperfusion. Prothrombin time 
(PT), partial thromboplastin time (PTT) and international normalised ratio (INR) are 
requested when appropriate. Arterial blood gas (ABG) analysis is recommended, as 
it provides prognostic information and may identify patients with respiratory failure 
and the need for early ventilatory support. Serum bicarbonate will be low in 
metabolic acidosis. HIV testing may be indicated. Thoracentesis should be done in 
patients with pleural effusion, which should include white cell and differential count 
and measurement of the pH, protein, glucose and lactate dehydrogenase and 
adenosine deaminase, Gram’s staining and culture, and Ziehl-Neelsen stain.9 
1.7.4.4. Other studies 
These include serological testing for atypical pathogens, tests for microbial antigens 
and/or antibodies, invasive diagnostic testing including bronchoscopy, and 
investigative tools such as polymerase chain reaction.9 Most experts recommend 
that they should not be performed routinely, especially in ED, because results are 
not available in time to affect therapy decisions, and the cost of care is increased 
unnecessarily.25 
1.8. Emergency department management of CAP 
Emergency department management involves resuscitation with rapid-focus clinical 
assessment if needed, medical history, physical examination, urgent relevant blood 
tests and investigations, and early appropriate administration of empiric antimicrobial 
therapy. 
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1.8.1. Patient who does need resuscitation 
Because of multiple potential complications associated with CAP the ABC (Airway, 
Breathing, Circulation) approach to resuscitation should be assessed and addressed 
first.10 
Clinical situations in which CAP patients might require urgent resuscitation include 
profound hypotension and septic shock complicating sepsis in the setting of 
pneumonia, terminal respiratory distress and respiratory failure with the immediate 
need for ventilatory support, cardiac arrest complicating pneumonia with multiple 
organ dysfunction, massive pleural effusion with cardiovascular collapse 
complicating CAP, and severe pneumonia in the setting of comorbities such as 
asthma, COPD, cardiac failure and end-stage AIDS. 
 Measurement of blood pressure (BP), pulse (P), temperature (T), Glasgow coma 
score (GCS), capillary refill time (CRT), pulse oximetry, urine output if indicated, and 
assessment of the arterial blood gas (ABG) are essential, and a more detailed 
examination of the patient follows as the situation permits.10 
1.8.1.1. Establishing an airway 
Administration of oxygen after basic airway opening manoeuvres (head tilt chin lift, 
and jaw thrust in cervical spine precaution in the case of trauma, extreme age, and in 
medical conditions such as rheumatoid disease, ankylosing spondylitis and Down’s 
syndrome26) should be considered. Adjunctive airways such as oro-pharyngeal and 
nasopharyngeal airways may be needed.  
Endotracheal intubation may be considered to secure the airway should the patient 
be in need of ventilatory support. If rapid sequence intubation (RSI) is indicated, a 
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prudent approach to avoid the use of etomidate as much as possible in the setting of 
septic shock is recommended by most experts so as to prevent adrenal insufficiency 
and other associated risks.27 However, if this agent has been used for induction, 
hydrocortisone 50 mg IV 6 hourly is recommended until the baseline serum cortisol 
level has been assessed.27 
1.8.1.2. Controlling the work of breathing 
Control of breathing is required when tachypnoea accompanies shock and 
mechanical ventilation and sedation decrease the work of breathing and have been 
shown to improve survival.10 
Arterial oxygen saturation should be restored to greater than 92% and ventilation 
controlled to maintain a partial pressure of carbon dioxide between 35 mmHg to 40 
mmHg.10 
1.8.1.3. Optimising the circulation 
Placing the patient supine, with legs raised above the level of the heart, does 
improve cardiopulmonary performance compared to Trendelenburg positioning.10
 
For 
patients in shock, haemodynamic stabilisation begins with IV access through a large-
bore peripheral line, and a central line should be inserted and measured. In cases of 
septic shock, correction or stabilisation of hypotension and inadequate perfusion with 
rapid, aggressive fluid administration as per EGDT protocol (Appendix B) is 
recommended (unless cardiogenic shock or extreme age is associated).10,28
 
Fluid resuscitation begins with isotonic crystalloid: 1-2 litres (20 mg/kg) of Ringer’s 
lactate (first choice) or normal saline solutions (second choice) are preferred.10 The 
colloid-versus-crystalloid resuscitation controversy remains despite evidence that 
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there is a slight increase in mortality when colloids are used for volume replacement 
in critically ill patients.29 Some studies have found a lower incidence of pulmonary 
oedema, and possible greater benefits in elderly patients with colloid resuscitation, 
although survival is not significantly improved.10 In the acute situation with severe 
shock, colloids may be considered to achieve rapid plasma expansion, and use less 
volume than crystalloids.10 
Vasopressor agents are used when there has been an inadequate response to 
volume resuscitation or when a patient has a contraindication to volume infusion.30 In 
relation to septic shock, unfortunately, no large, prospective, randomised, and well-
conducted studies to guide pharmacological management are available so far.31  
The conventional recommendation of either norepinephrine or dopamine as first-line 
therapy to correct septic hypotension and epinephrine limited to patients in whom 
volume resuscitation (3 to 4 litres) and first-line drugs have failed to restore sufficient 
BP has recently been challenged.31 Furthermore, while dobutamine was also 
previously considered the preferred drug to increase cardiac output in critically ill 
patients and recommended as the agent of choice in septic shock patients, this has 
also been questioned.32,33  
1.8.1.4. Other considerations 
A focused physical examination from head to toes should be performed and special  
attention should be paid to the respiratory system by looking for use of accessory 
muscles of respiration, palpation for increased or decreased tactile fremitus, and  
percussion for dullness or stony dullness, reflecting underlying consolidated lung and 
pleural fluid, respectively. The auscultation may reveal crackles, bronchial breath 
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sounds, and possibly a pleural friction rub and signs of bronchial secretions (rhonchi 
and wheezing).16 
A chest radiograph is a valuable initial examination with further testing dictated by 
clinical suspicion. If indicated complex imaging studies (computed tomography) 
should wait until the patient is resuscitated.10 
Urgent blood tests should be done, including full blood count with differential, urea 
and electrolytes, liver function test, and C-reactive protein, coagulation studies, 
lactate, glucose, and blood cultures. Care should be taken to obtain urinalysis in all 
patients and perform pregnancy testing in all women of child-bearing age. 
It is also important to identify and correct metabolic derangement (hypoglycaemia, 
hypocalcaemia) and consider the need of early mechanical ventilation with PEEP, 
when indicated. Early administration of antibiotics and anticipation of possible need 
for vasopressors and stress-dose hydrocortisone should be done.34 Severe fever, 
treatment with oral or IV paracetamol should be considered, and care should be 
taken to avoid hypothermia. If appropriate, chest decompression with therapeutic 
thoracentesis or sometimes with tube thoracostomy, in the presence of a pleural 
effusion, should be considered.10 
1.8.1.5. Corticosteroid therapy 
Studies in early and late septic shock have shown that low-dose corticosteroids 
reduce the duration of vasopressor requirements and should be considered for use 
in patients who remain hypotensive despite adequate fluid, vasopressor and oxygen 
delivery strategies, or in patients who are not tolerating vasopressor agents.35 In this 
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regard hydrocortisone 50 mg IV 6 hourly is the recommended dose.35 Corticosteroid 
therapy is also used in suspected deficiency states. 
1.8.1.6. Achieving end points of resuscitation10,22 
The goal of resuscitation is to restore and maintain adequate tissue perfusion as 
indicated by normalisation of BP, and pulse rate, increased urine output, improved 
mentation, skin perfusion, decreased lactate, and resolving metabolic acidosis. 
A goal-directed approach at achieving urine output above 0, 5-1 mL/kg/h, central 
venous pressure (CVP) 8 to 12 mm Hg, mean arterial pressure MAP 65 to 90 mm 
Hg, central venous oxygen saturation (Scvo2) above 70% during ED resuscitation of 
the shock patient significantly decreases mortality. 
1.8.2. Patient who does not need resuscitation 
1.8.2.1. Medical history 
The clinical diagnosis will be directed at looking for any of the symptoms of CAP as 
well as any of the risk factors associated. 
1.8.2.2. Physical examination 
Measurement of blood pressure, pulse, temperature, Glasgow coma scale, capillary 
refill time, and pulse oximetry should be done. Because of multiple potential 
complications associated with CAP a full physical examination, from head to toes, 
should be performed. Examination of the head, ears, eyes, nose, throat, and lymph 
nodes should be documented. Cardiovascular status should be assessed by 
auscultating for normal and abnormal heart sounds, the regularity of the cardiac 
beat, and the presence/absence of murmurs. Pulmonary examination for the use of 
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accessory muscles of respiration, palpation for increased or decreased tactile 
fremitus, and percussion for dullness or stony dullness, reflecting underlying 
consolidated lung and pleural fluid, respectively, should be undertaken. Auscultation 
for crackles, bronchial breath sounds, and possibly a pleural friction rub and signs of 
bronchial secretions (rhonchi and wheezing) should also be undertaken.16 The status 
of the abdomen should be assessed for possible distension, tenderness, and 
organomegaly. Hydration status and skin examination should be documented.  
1.8.2.3. Other considerations  
A chest radiograph should be requested and the site of care should be decided. If 
indicated, urgent blood tests should be done, including full blood count with 
differential, urea and electrolytes, liver function test, and C-reactive protein, lactate, 
glucose, and blood cultures.  Pregnancy tests should be performed in all women of 
child-bearing age. Early administration of antibiotics is recommended and 
consideration should be given to fever and pain treatment with paracetamol and/or 
non-steroidal anti-inflammatory drugs. 
1.8.3. Empiric antimicrobial therapy 
The first dose of the antimicrobial should be given as soon as possible, within the 
golden hour (as soon as 4 hours after disease presentation, if possible), and has 
been shown to improve survival and reduce length of stay of hospitalised CAP 
patients.36 
Although an aetiological agent is frequently not identified, the distribution of 
organisms remains approximately 70% to 80% typical bacterial respiratory 
pathogens, and about 20% to 25% atypical microorganisms. Co-infection with both 
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typical and atypical bacteria has been reported and may increase mortality and 
length of hospitalisation.37 Mortality reduction has been described when treatment 
covers both typical and atypical pathogens and clinically it is not possible to reliably 
differentiate between the two types of bacterial infection. For these reasons all 
guidelines recommend empiric antimicrobial agents to be started in ED for both 
typical and atypical pathogens coverage.37 
Different options for empiric antibiotic therapy are offered and individual choice of 
treatment is guided by thorough knowledge of commonly encountered pathogens in 
the region or practice environment and a full appreciation of their usual susceptibility 
patterns. Significant differences in microbial susceptibilities have been noted, not 
only within the different geographical areas of South Africa, but also between the 
public and private sector.9 A further recommendation is that since recent exposure to 
an antibiotic (in the past 3 months) is a risk factors for antibiotic resistance, 
particularly to that class of antibiotics, patients presenting with pneumonia should be 
asked about recent antibiotic exposure. If they have recently been exposed to a 
particular class of antibiotics, continued or repeated use of that class of antibiotics is 
not recommended, or, in the case of a beta-lactam, an agent in that same class with 
a broader spectrum should be used.9 The South African guideline for patients with 
CAP is described as follows (Appendix C).9 Few of the recommended treatment 
regimens have been validated in prospective studies. 
1.8.3.1. Patients treated at home 
1.8.3.1.1. Young patients < 65 years of age, without comorbid illness 
In young patients, below the age of 65 years and without comorbid illness, the 
treatment of choice is high-dose oral amoxicillin (Appendix D). 
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1.8.3.1.2. Elderly patients ≥ 65 years and/or adults with comorbidity, including 
patients with HIV infection 
Agents available for oral outpatient use, which are recommended for use in the 
elderly (≥ 65 years), for patients with co-morbid illness, and for sicker patients, are 
amoxicillin-clavulanate or selected oral cephalosporins (i.i: cefuroxime axetil or 
cefpodoxime). 
1.8.3.1.3. Alternative antibiotics for both situations 
1.8.3.1.3.1. Fluoroquinolones 
Fluoroquinolones with extended Gram-positive cover (moxifloxacin and gemifloxacin) 
are the preferred agents because of their superior microbiological efficacy against S. 
pneumoniae. Levofloxacin, which is now recommended at the higher dose (750 mg 
daily or 500 mg 12-hourly), is also a suitable option. However, in order to limit the 
development of resistance, it is recommended that these agents are not used as 
routine first-line therapy, but rather are reserved for patients with severe allergy to 
standard beta-lactam agents, for known or suspected cases of infection with highly 
penicillin-resistant pneumococci or other resistant infections, and for patients in 
whom initial therapy with other antimicrobial agents has failed. These antibiotics also 
provide good cover, as monotherapy, for infections with the so-called "atypical 
pathogens". 
1.8.3.1.3.2. Macrolides/Azalides  
On the basis of current information on the mechanism, prevalence, and significance 
of macrolide/azalide resistance in S. pneumoniae in South Africa, these agents are 
not routinely recommended as monotherapy for the treatment of CAP in many 
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situations. The prevalence of resistance of these agents appears to be high in many 
areas, particularly in the private sector in South Africa. In areas known to have a low 
prevalence of macrolide resistance, such as in many of the public sectors, the 
continued use of macrolides/azalides as monotherapy in young, previously healthy 
adults, who have not recently been exposed to antibiotics, may still be acceptable. A 
thorough knowledge of common pathogens and their susceptibility pattern in one’s 
own area of practice is therefore essential. 
1.8.3.1.3.3. Telithromycin  
Telithromycin has in vitro activity against macrolide/azalide-resistant S. pneumoniae. 
Like the fluoroquinolones, it is recommended that this agent is not used as routine 
first-line therapy, but reserved for patients with severe allergy to standard beta-
lactam agents, for known or suspected cases of infection with highly penicillin-or 
macrolide resistant pneumococci, and for cases in which initial therapy with other 
antimicrobial agents has failed. 
1.8.3.1.3.4. Tetracycline/Doxycycline 
The considerable and increasing resistance of S. pneumoniae to 
tetracycline/doxycycline in South Africa, limits its general use as monotherapy for 
CAP. 
1.8.3.2. Hospitalised patients  
1.8.3.2.1. Young patients <65 years of age, with no comorbid illness 
The treatment of choice is high doses of parenteral penicillin or ampicillin or 
amoxicillin (Appendix D). Alternative therapy may be an intravenous anti-
pneumococcal fluoroquinolone, with the same considerations as described above. 
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1.8.3.2.2. Elderly patients ≥ 65 years and/or adults with comorbidity, including 
patients with HIV infection 
The treatment of choice is either amoxicillin-clavulanate or a selected second-
generation cephalosporin (cefuroxime) or a selected third-generation cephalosporin 
(ceftriaxone or cefotaxime). It is further recommended that these agents be given 
parenterally initially, at least until the temperature settles. 
1.8.3.3. Additional therapy for both non-hospitalised and hospitalised cases  
A macrolide, azalide, tetracycline or telithromycin is recommended on its own or as 
additional therapy for any patient being treated with a beta-lactam antibiotic in the 
case of suspected or proven infection with the so-called atypical pathogens. While 
clinical features often do not allow for an accurate differentiation of atypical infections 
from the more common bacterial causes, it may be appropriate to add one of these 
agents to standard therapy in cases with atypical or unusual features, or in cases not 
responding to initial antibiotic treatment. Also the guideline recommends that in the 
more severely ill, hospitalised patient with CAP, a macrolide/azalide should be added 
to the standard beta-lactam therapy, because of several studies showing improved 
outcomes in those cases treated with such therapy (see below).  
1.8.3.4. Critically ill adults 
The treatment of choice is a combination of parenteral amoxicillin-clavulanate or a 
parenteral second-generation cephalosporin (cefuroxime), or a third-generation 
cephalosporin (ceftriaxone or cefotaxime), together with an aminoglycoside 
(gentamicin or amikacin or tobramycin) and a macrolide (erythromycin, 
clarithromycin or azithromycin). The aminoglycoside is added initially because of the 
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relative high prevalence of CAP associated with aerobic Gram-negative bacilli 
documented previously in various intensive care unit studies in South Africa. 
Alternative treatment may include an anti-pneumococcal fluoroquinolone, particularly 
in the setting of severe beta-lactam allergy. However, there is no data on whether 
these agents are adequately effective as monotherapy in critically ill cases, and 
therefore at present, in this setting, it is recommended that if they are used it should 
be together with another antibiotic, such as a beta-lactam agent or an 
aminoglycoside. 
1.8.3.5. Combination therapy 
There is emerging evidence that in patients with severe CAP, combination antibiotic 
therapy, most commonly the addition of a macrolide agent to standard beta-lactam 
therapy, may be associated with a better outcome than monotherapy. Although the 
studies have been retrospective or purely observational in design, the benefit in 
outcome has been shown, particularly in sicker, hospitalised patients with 
pneumonia, including the sub-set of patients with bacteraemic pneumococcal 
infections. The current guideline recommends combination antibiotic therapy in 
severely ill patients with CAP admitted to hospital for intravenous antibiotic therapy, 
in line with most international pneumonia guidelines. 
1.9. CURB-65 and CRB-65 severity of illness scores 
1.9.1. Overview 
CAP presents to physicians as a wide spectrum of illness severity, varying from mild 
self-limiting infection to life-threatening and occasionally fatal disease.38 This breadth 
of illness severity is reflected in the variable mortality rates reported by studies of 
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CAP in different clinical settings.38 The decision regarding the most appropriate site 
of care of a patient with CAP is one of the most important decisions in the overall ED 
management of these patients. It has consequences both for the level of treatment 
received by the patient as well as the overall costs of treatment.38 Such decisions are 
best informed by an accurate assessment of the severity of illness at presentation 
and therefore the likely prognosis. The recognition of patients at low risk of mortality 
and/or complications and therefore suitable for treatment out of hospital has the 
potential to reduce inappropriate hospitalisation and consequently inherent medical 
costs.38 When hospital admission is required, further management is also influenced 
by illness severity.38 This includes the extent of the microbiological investigation, the 
choice of initial empiric antimicrobial chemotherapy and its route of administration, 
the duration of hospital treatment and the level of nursing and medical care.38 
Early identification of patients at high risk of death allows early initiation of 
appropriate antibiotic therapy and especially early admission to an ICU, factors that 
may significantly impact on outcome. Clinicians will often make these decisions 
based on their assessment of the severity of illness of their patient with CAP. A 
number of severity of illness assessment tools have been developed to assist in 
such decision making.  
The CURB-65 severity of illness score is one of the two most extensively studied and 
validated clinical practice guideline tools that have been recognised and 
recommended by experts.5,22,37 This severity assessment tool was proposed by the 
British Thoracic Society and later modified by Neill et al. 22,38 It was developed mainly 
as a means of identifying patients with more severe CAP at higher risk of mortality.22 
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The CURB-65 score firstly was validated in a study of over 1 000 prospectively 
studied patients with CAP from the United Kingdom, New Zealand and the 
Netherlands.37 Since then the CURB-65 score has been studied in over 20 000 
patients representing a mix of patients seen both in the community and in hospitals 
and all studies reported findings similar to the derivation studies.37 
For the CURB-65 score, one point is assigned for each of the following parameters, 
if present, namely confusion, urea >7mmol/l, respiratory rate ≥ 30/min, blood 
pressure (systolic < 90 mmHg and/or diastolic ≤ 60 mmHg) and age ≥ 65 years, thus 
enabling patients to be stratified according to increasing risk of mortality (score 0, 
0.7%, score 1, 2.1%, score 2, 9.2%, score 3-5, 15-40%) (Figure 1.1).22,37 
It is suggested that patients with scores 0 and 1 are at low risk of mortality and may 
be suitable for management as hospital outpatients.39,40 Patients with a score of 2 
are at intermediate risk of mortality and should be considered for hospital-supervised 
treatment.38 Patients with scores 3 to 5 are at higher risk of mortality and correspond 
to those who may need high care or ICU care.22 
A more simplified tool, the CRB-65 score, was subsequently reported and studied, in 
which the only laboratory value of the CURB-65 score, namely the blood urea 
nitrogen, was not required (Figure 1.1).22,37 For this scoring system, one point is 
assigned for each of the following parameters, if present: confusion, respiratory rate 
≥ 30/min, blood pressure (systolic < 90 mm Hg and/or diastolic ≤ 60 mm Hg) and age 
≥ 65 years.22,37 For this scoring system, the risk of mortality for each of the scores is: 
score 0, 1.2%, score 1, 5.3%, score 2, 12.2%, score 3-4, up to 33%.37 
It is suggested that patients with a score of 0 are at low risk of mortality and may be 
suitable for management as hospital outpatients.39,40 Patients with a score of 1 or 2 
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are at intermediate risk of mortality and should be considered for hospital-supervised 
treatment.22 Patients with scores 3 to 4 are at high risk of mortality and correspond to 
those who may need high care or ICU care.22 
This modified tool was validated with results similar to those of the CURB-65 score 
(Table 1.1).5,22,37 This more simplified score may be particularly valuable in 
developing countries, especially in poor resources settings, since it obviates the 
need to measure the blood urea level.  
In order to better determine the presence or not of confusion, as used in the CRB-65 
severity of illness score, one can do the abbreviated mental test, as described below. 
1.9.2. The abbreviated mental test as used in the CRB-65 score 
This quick screening test (Table 1.2) was first introduced by Hodkinson in 1972 to 
rapidly assess elderly patients for the possibility of dementia.39 Its uses in medicine 
have become somewhat wider (i.e. to assess for confusion or other cognitive 
impairment)40 and data recommends its use in ED as the generally accepted 
practice.41 
As modified for South African conditions (Table 1.3), a number of questions are put 
to the patient and each of them correctly answered scores one mark, for a total of 10 
marks.7,8 Confusion is defined as a mental test score of 8 or less or new 
disorientation in the patient, place or time as used in CURB-65 and CRB-65 severity 
of illness scores.22 
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Figure 1.1: Severity of illness assessment: the CURB-65 score22 
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Figure 1.2: Severity of illness assessment: the CRB-65 score22 
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. Respiratory rate ≥30/min 
. Blood pressure (SBP <90 mm Hg or DBP ≤60 
mm Hg) 
. Age ≥65 years 
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Table 1.2: The abbreviated mental test39,40  
 
 - Patient’s age 
 - Patient’s date of birth 
 - Time (to nearest hour) 
 - Year 
 - Hospital name 
 - Recognition of two persons (e.g. doctor, nurse) 
 - Recall address 
 - Date of First World War 
 - Name of monarchs 
 - Count backwards 20 to 1 
 
 
Table 1.3: The abbreviated mental test modified for South African conditions 
  
- Patient’s age 
 - Patient’s date of birth 
 - Time (to nearest hour) 
 - Year 
 - Hospital name 
 - Recognition of two persons (e.g. doctor, nurse) 
 - Recall address  (1) 
 - Date of  the first democratic election in South Africa  (2) 
 - Name of the current state president  (3) 
 - Count backwards 20 to 1 
 
1 = Ability of patient to recall his/her address checked with the home address given to the Clerks. 2 = 1994, and 3 
= Jacob Zuma. 
30 
 
1.10. Study aim 
To determine whether it would be useful to introduce the CRB-65 severity of illness 
score in the routine evaluation of patients with community-acquired pneumonia in the 
Helen Joseph Hospital Emergency Department. 
1.11. Study objectives 
1. To determine what criteria Helen Joseph Hospital Emergency Department 
doctors use in their decision of whether to admit or discharge CAP patients.  
2. To determine the frequency with which the CRB-65 severity of illness score is 
used in current practice by the Helen Joseph Hospital Emergency Department 
doctors for admitting or discharging CAP patients.  
3. To determine the potential performance of the CRB-65 severity of illness 
score in the management of patients with CAP in the Helen Joseph Hospital 
Emergency Department. 
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CHAP 2. MATERIALS AND METHODS 
2.1. Ethics 
The research was approved by the Human Research Ethics Committee of the 
University of the Witwatersrand (protocol approval number M10912 – see appendix 
E). The Helen Joseph Hospital Emergency Department doctors were informed about 
the study and requested to volunteer to participate (Appendix F). Using a subject 
information sheet, research participants were informed (in the language they were 
most comfortable with) about the study.  
Written informed consent was obtained from the patients (Appendix G). When the 
patient was unable to give informed consent, this was requested from a spouse or 
partner, a parent, a grandparent, an adult child or a brother or sister of the patient 
(Appendix H). When the patient was unable to give consent and none of his/her 
relatives were present, the patient was automatically enrolled in the study and a 
retrospective consent (Appendix I) was obtained from the patient once his/her 
mentation was improved to acceptable baseline. Confidentiality was maintained by 
not using patient names but giving a unique PIN to each patient, starting from 001 
(Appendix J). 
2.2. Study design 
This was a prospective, observational, hospital-based study of a convenience 
sample of 152 patients over a 12-week period between February 2011 and April 
2011. 
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2.3. Study sample, study setting and population 
The study was conducted in the Emergency Department at Helen Joseph Hospital in 
Auckland Park, Johannesburg. 
2.3.1. Inclusion criteria 
• Patient aged 18 years or above evaluated as having CAP in the ED of HJH. 
• CAP was defined as the presence of two or more of the following:2 
o Altered breath sounds and/or signs of lung consolidation 
o Fever  
o Rigors 
o Sweats 
o Cough with or without sputum production 
o Pleuritic chest pain 
o Cyanosis 
o Shortness of breath 
o Tachypnoea 
• All patients were required to have radiological confirmation of the diagnosis of 
pneumonia. 
2.3.2. Exclusion criteria 
• Patients with suspected or confirmed aspiration pneumonia. 
• Patients with suspected or confirmed chemical pneumonitis. 
• Patients with suspected or confirmed Pneumonocystis jirovecii pneumonia. 
• Patients with suspected or confirmed pulmonary tuberculosis. 
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2.4. Data collection 
The study proceeded as follows: 
• Prior to the start the candidate explained to ED colleagues that he was 
conducting a study to determine what the criteria were that were used by the 
HJH ED for admitting or discharging CAP patients. He requested their 
participation in the study, following informed consent, and discussed this with 
them in general terms so as not to change their clinical practice (Appendix F). 
• The candidate requested the ED doctors to call him every time they finished 
their evaluation/management of a CAP patient.  
• The candidate interviewed the patient and requested his/her participation in 
the study, with informed consent. The candidate confirmed that the cases 
fitted the inclusion criteria and then filled in the case report form (Appendix K). 
In order to protect the confidentiality of the patients, each patient was given a 
unique PIN starting from 001, which was entered into the case report form. 
• Following this, the candidate ascertained from the ED doctor on what basis 
the doctor had elected to admit the patient to hospital or to discharge the 
patient home. The question was open ended. e.g. “On what basis did you 
decide to admit the patient to hospital or to discharge the patient home?” All 
reasons given were recorded (Appendix K).  
• The candidate assessed the severity of illness of the patient using the CRB-
65 score. This was also entered into the case report form.   
• The candidate followed the progress of the patient’s illness. For those 
admitted to HJH, the candidate followed the cases until discharge, step-down 
or death. The clinical details were entered into the case report form. For those 
stepped down to Selby Hospital, the candidate followed the progress of the 
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patient’s illness telephonically with an identified Selby Hospital permanent 
medical officer. The patients who were discharged home were asked to 
supply a contact number (kept confidential) in order to contact them or their 
family to determine the progression of their infection (Appendix J). 
2.5. Outcome measures 
Outcome criteria of CAP patients included: 
o Discharge, step-down or death. 
o For those admitted to hospital, resolution of clinical symptoms and 
signs – time to clinical stability. Time to clinical stability was determined 
according to a validated rule that defined clinical stability as the first 
day that most of the following criteria were simultaneously achieved: 
SBP ≥ 90 mmHg; RR ≤ 24 breaths/min; oxygen saturation ≥ 92%, 
temperature ≤ 37.2°C; ability to tolerate oral intake; and basel ine 
mental status.42 Time to clinical stability was calculated by subtracting 
the admission date from the first date that the patient was determined 
to be clinically stable.42 Length of hospital stay was calculated by 
subtracting the hospital admission date from the hospital discharge 
date.42 
2.6. Sample size estimation 
It has previously been observed that the average proportion of patients diagnosed 
with CAP in the ED of the HJH is 7%. However, our experience showed that this 
proportion can rise to 15%. Using a significance level of 5%, the minimum sample 
size required to detect a difference from 7% to 15% with a power of 95% is 144 
(Stata version 11 command). Study participants may withdraw for multiple reasons, 
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and the percentage of withdrawals can be estimated as 10%. The sample size was 
then increased by 15 to give a minimum sample size of n=159. 
2.7. Data analysis 
Collected data was captured on a personal computer using Excel software and 
analysed in Excel and Stata version 11, with the help of a statistician. 
Descriptive statistics were done using frequencies, cross-tabulations, bar charts and 
histograms. Means and standard deviations for normally distributed continuous 
variables were also calculated and reported. For non-normally distributed continuous 
variables, medians and their associated ranges were calculated and reported. 
Associations between categorical outcomes were formally tested using the Chi-
squared test and the Fisher’s exact test (FET) when the expected numbers of 
subjects in the cells were less than five. The Chi-squared test assumes that each cell 
has an expected frequency of five or more, but the FET has no such assumption. 
Associations between non-normally distributed continuous variables were tested 
using the non-parametric Spearman’s correlation. To test for agreement between 
two categorical variables, the kappa test statistic was used. Results were presented 
using p-values. 
2.8. Significance level 
Two-sided statistical tests at the 5% significance level were used throughout the 
analysis. A p-value of less than 0.05 was considered statistically significant. 
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2.9. Software 
All data was entered and stored in a Microsoft Excel R (Microsoft office 2007, 
Microsoft Corporation) spreadsheet. All analysis was conducted using Stata version 
11 and Excel. 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
CHAP 3. RESULTS 
3.1. Baseline clinical characteristics 
A total of 159 patients, representing a diverse spectrum of ethnic groups, were 
enrolled in the study over the three-month period between February 2011 and April 
2011. Seven patients were later excluded because they were subsequently 
confirmed to have pulmonary tuberculosis, and therefore 152 patients were included 
in the final analysis. The baseline clinical characteristics (age, gender, abbreviated 
mental test modified for South African conditions (AMTMSAC), systolic and diastolic 
blood pressure (BP), heart rate, respiratory rate, and body temperature) are 
summarised in Table 3.1 and Table 3.2. 
Table 3.1: Baseline clinical characteristics of the study patients 
Variable Mean ± SD Median (Range) 
Age (years) 39.7 ± 13.6 36.5 (20 to 87) 
Systolic BP (mmHg) 118.8 ± 17.6 114 (86 to 172) 
Diastolic BP (mmHg) 71.4 ± 12.2 72 (35 to 100) 
Heart rate (beats/min) 100.1 ± 20.3 103 (58 to 158) 
Respiratory rate 
(breaths/min) 
23.9 ± 5.1 23.5 (14 to 38) 
Temperature (ºC) 37.7 ± 0.9 37.8 (36 to 41) 
SD: standard deviation, BP: blood pressure 
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Table 3.2: Other baseline clinical characteristics of the study patients 
Variables  N (%) 
Gender Female 79 (52%) 
 
Male 73 (48%) 
AMTMSAC 
10/10 149 (98%) 
 
8/10 2 (1.3%) 
 
6/10 1 (0.7%) 
AMTMSAC: Abbreviated Mental Test Modified for South African Conditions 
3.1.1. Age 
The median age was 36.5 years and the range was from 20 to 87 years, as shown in 
Table 3.1. The frequency distribution of the ages of the patients is shown in Table 
3.3 and the corresponding frequency histogram is given in Figure 3.1. The majority 
of the patients 140/152 (92.1%) were less than 65 years of age and the remaining 
12/152 (7.9%) were aged 65 years and above. 
 
 
 
 
 
 
 
 Table 3.3: Age frequency d
Age (observed value)
Age 
interval 
N 
[17-24] 18 
[25-32] 37 
[33-40] 32 
[41-48] 30 
[49-56] 18 
[57-64] 5 
[65-72] 10 
[73-80] 2 
        152 
 Number in brackets represents range of ages (years) 
Figure 3.1: Histogram for age distribution
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istribution 
 
% Cumulative % 
11.84 11.84 
24.34 36.18 
21.05 57.24 
19.74 76.97 
11.84 88.82 
3.29 92.11 
6.58 98.68 
1.32 100.00 
100.00  
 
 
 
 3.1.2. Gender 
Almost half (79/152 (52%)
making up 73 of the 152 patients 
3.2 show the gender distribution by age group (using a cut
was no statistically significant difference in gender distribution by age group (p = 
0.646). 
Table 3.4: Gender distribution by age group
Age interval 
Less than 65 years 72 (91.14%)
65 years and above 7 (8.86%)
Total 79 (100%)
Note: column percentages in brackets
 
Figure 3.2: Age bar chart by 
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) of all the enrolled patients were females
(48%), as shown in Table 3.2. Table 3.4 and Figure 
-off of 65 years). 
 
Female Male Total 
 68 (93.15%) 140 
 5 (6.85%) 12 
 73 (100%) 152 
 
gender 
, with males 
There 
 
 3.1.3. Abbreviated Mental Test Modified for South African Conditions 
(AMTMSAC) 
The majority (149/152 (98%)
AMTMSAC score of 10/10, a 
(0.7%) had a score of 6/10. This is shown in Table 3.2 and Figure 3
 
Figure 3.3: AMTMSAC pie-
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) of the patients enrolled in the study had a normal 
few (2/152 (1.3%)) had a score of 8/10 and only 1/152 
.3.
chart 
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3.1.4. Systolic blood pressure 
As shown in Table 3.1, the median systolic BP for all the patients enrolled was 114 
mmHg and ranged from 86 mmHg to 172 mmHg. The frequency histogram for 
systolic blood pressure is shown in Figure 3.4. 
Figure 3.4: Systolic BP histogram 
 
sbp: systolic blood pressure  
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3.1.5. Diastolic blood pressure 
As shown in Table 3.1, the median diastolic BP for all the patients was 72 mmHg 
and ranged from 35 mmHg to 100 mmHg. The frequency distribution of diastolic BP 
is shown in Figure 3.5. 
Figure 3.5: Diastolic BP histogram 
 
dbp: diastolic blood pressure 
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3.1.6. Heart rate 
As shown in Table 3.1, the median heart rate for all the patients was 103 beats per 
minute and ranged from 58 beats per minute to 158 beats per minute. The frequency 
distribution of heart rate is shown in Figure 3.6. 
Figure 3.6: Heart rate histogram 
 
hr: heart rate 
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3.1.7. Respiratory rate 
As shown in Table 3.1, the median respiratory rate for all the patients was 23.5 
breaths per minute and ranged from 14 breaths per minute to 38 breaths per minute. 
The frequency distribution of respiratory rate is shown in Figure 3.7. 
 
Figure 3.7: Respiratory rate histogram 
 
rr: respiratory rate 
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3.1.8. Body Temperature 
As shown in Table 3.1, the median body temperature for all the patients was 37.8 ºC 
and ranged from 36 ºC to 41 ºC. The frequency distribution of temperature is shown 
in Figure 3.8. 
Figure 3.8: Body temperature histogram 
 
temp: temperature 
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 3.2. Admission/discharge decision
Overall, 68/152 (45%) of all the enrolled patients were managed as in
patients and the remaining 84/152 (55%) were treated as outpatients. This 
information is also shown in Figure 3
Figure 3.9: Admission/discharge 
3.2.1. Admission/discharge data
The admission/discharge data p
(82%) of the in-hospital patients were females and 12/68 (18%) were males. Of 
those treated as outpatients, 23/84 (27%) were females and 61/84 (73%) were 
males. Significantly more females were managed as in
and significantly more males were managed as outpatients than females (p < 0.001).
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.9. 
data 
 by gender group 
er gender group is shown in Table 3
-hospital patients than males
-hospital 
 
.5. Overall 56/68 
, 
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Table 3.5 Admission/discharge by gender group 
Gender 
Decision 
Total 
Admitted Discharged 
M 12 (18%) 61 (73%) 73 (52%) 
F 56 (82%) 23 (27%) 79 (48%) 
Total 68 (100%) 84 (100%) 152 (100%) 
 Note: column percentages are given in brackets 
3.2.2. Admission/discharge by age group 
Table 3.6 shows the cross-tabulation of the decision on management of patients as 
either in-hospital patients or as outpatients by age group (using a cut-off of 65 
years). Figure 3.10 gives the visual display. No significant differences were observed 
in the age distribution between the in-hospital patients and outpatients (p = 0.702). 
Table 3.6: Admission/discharge decision by age group (cut-off of 65 years) 
Age interval Admitted Discharged Total 
Less than 65 years 62 (91.18%) 78 (92.86%) 140 (92.11%) 
65 years and above 6 (8.82%) 6 (7.14%) 12 (7.89%) 
Total 68 (100%) 84 (100%) 152 (100%) 
Note: column percentages are given in brackets 
 
 
 
 
 
 Figure 3.10: Admission/discharge 
3.2.3. Admission/discharge criteria used by ED doctors for admission 
decisions 
Table 3.7 shows the criteria used by HJH ED doctors in deciding site of care for 
patients, arranged in decreasing order of frequency. The corresponding relative 
frequencies are given in the table.
because for some patients more than one criterion was used. 
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data by age group 
 The total of 193 exceeds our sample size of 152 
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Table 3.7: Criteria used by the HJH ED doctors for site of care decisions  
Criterion N % 
CXR 80 41.50% 
Haem para 50 25.90% 
Blood 21 10.90% 
O2 Sat 20 10.40% 
Fever 5 2.60% 
CURB-65 4 2.10% 
CRB-65 3 1.60% 
Adv RVD 2 1.00% 
Tachycardia 2 1.00% 
RD 2 1.00% 
IV Antibiotic 1 0.50% 
Dehydration 1 0.50% 
Ren dysf 1 0.50% 
SOB 1 0.50% 
TOTAL 193 100 
CXR: chest radiograph, Blood: blood test results of the patients, Adv RVD: advanced retroviral disease, O2 sat: 
saturation of oxygen on room air, Haem. para: haemodynamic parameters of the patients, Ren dysf: renal 
dysfunction, RD: respiratory distress, and SOB: shortness of breath, IV Antibiotic: patient’s need for intravenous 
antibiotics. 
As shown in Table 3.7, the criteria used by the Helen Joseph Hospital Emergency 
Department doctors, in decreasing order of frequency, were as follows. Firstly, the 
chest radiograph was the commonest criterion used (80/193 (41.5%)). Secondly, it 
was the haemodynamic parameters of the patient (50/193 (25.9%)). Thirdly, it was 
the blood test results (full blood count, urea and electrolyte, C-reactive protein, liver 
function test) of patients (21/193 (10.9%)). Fourthly, it was oxygen saturation of the 
patient on room air (20/193 (10.4%)). Fifthly, it was the presence of fever (5/193 
 (2.6%)). Sixthly, the CURB
65 score (3/193 (1.6%)) was used. Eighthly, there were three criteria with the same 
relative frequency (2/193 
associated co-morbidity, the presence of tachycardia, and the presence of 
respiratory distress. Lastly, there were four
(1/193 (0.5%) each), namely the need for intravenous antibiotics, shortness of 
breath, the presence of renal dysfunction, and dehydration. This 
shown in Figure 3.11. 
Figure 3.11: Criteria used by the 
CXR: chest radiograph, Blood: blood test results of the patients, 
saturation of oxygen on room air, Haem. p
dysfunction, RD: respiratory distress, and SOB: shortness of breath, IV Antibiotic: patient’s need for intravenous 
antibiotics. 
Table 3.8 shows the distribution of the criteria for the site of care decisions used
the HJH ED doctors. Figure 3
distribution. 
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-65 score (4/193 (2.1%)) was used. Seventhly, the CRB
(1%) each), namely advanced retroviral disease as 
 criteria with the same least 
ED doctors for site of care decisions
Adv RVD: advanced retroviral disease, O2 sat: 
ara: haemodynamic parameters of the patients, Ren dys
.12 shows the clustered bar chart for this same 
-
percentage 
information is 
 
 
f: renal 
 by 
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Table 3.8: Admission and discharge decisions according to criteria made  
Criterion 
Admitted Discharged Total 
N % N % N % 
CXR 47 49 33 34 80 41.5 
Haem. Para 3 3 47 48 50 25.9 
Blood 6 6 15 15 21 10.9 
O2 sat 20 21 _ _ 20 10.4 
Fever 5 5 _ _ 5 2.6 
CURB-65 2 2 2 2 4 2.1 
CRB-65 2 2 1 1 3 1.6 
Adv RVD 2 2 _ _ 2 1.0 
Tachycardia 2 2 _ _ 2 1.0 
RD 2 2 _ _ 2 1.0 
IV Antibiotic 1 1 _ _ 1 0.5 
Dehydration 1 1 _ _ 1 0.5 
Ren dysf 1 1 _ _ 1 0.5 
SOB 1 1 _ _ 1 0.5 
Total 95 100 98 100 193 100 
CXR: chest radiograph, Blood: blood test results of the patients, Adv RVD: advanced retroviral disease, O2 sat: 
saturation of oxygen on room air, Haem. para: haemodynamic parameters of the patients, Ren dysf: renal 
dysfunction, RD: respiratory distress, and SOB: shortness of breath, IV Antibiotic: patient’s need for intravenous 
antibiotics 
 
 
 
 
 
 
 
 
 
 
 Figure 3.12: Admission/discharge 
CXR: chest radiograph, Blood: blood test results of the patients, 
saturation of oxygen on room air, Haem. p
dysfunction, RD: respiratory distress, an
antibiotics 
Significant differences were noted in the
decisions (p < 0.001) by the HJH ED doctors in 
more frequently in admitting patients compared to all other criteria
haemodynamic parameters were used more frequently for discharging patients
compared to all other criteria (Figure 4.12).
3.2.4. Admission/discharge dec
Only on three occasions was the CRB
admission decisions 3/193 (1.55%).
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decisions by criteria  
Adv RVD: advanced retroviral disease, O2 sat: 
ara: haemodynamic parameters of the patients, Ren dys
d SOB: shortness of breath, IV Antibiotic: patient’s need for intravenous 
 criteria used for admission and discharge 
that the chest radiograph was used 
 
isions by CRB-65 score 
-65 score utilised out of 193 criteria for 
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 3.3. Outcomes  
3.3.1. Time to clinical stability (in days)
The distribution of number of days to clinic
Figure 3.13. The total of 63 in
that occurred from an overall total of 68 in
Table 3.9: Time to clinical stability 
Day of 
stability N 
1 22 
2 34 
3 7 
Total 63 
 
Figure 3.13: Time to clinical stability
The median time to clinical stability (in days) for all in
and ranged from one to three 
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al stability is shown in Table 3.9 and 
-hospital patients in the table excludes the five deaths 
-hospital patients. 
(in days) 
% 
35 
54 
11 
100 
 (days) 
-hospital patients was 
days. 
 
two days 
 3.3.2. Length of hospital stay (in days)
The distribution of the length of hospital st
Figure 3.14. The total of 63 in
that occurred from an overall total of 68 in
Table 3.10: Length of hospital stay (in days)
Days of 
hospital stay N 
2 to 4 16 
5 to 7 33 
8 to 10 11 
11 to 13 3 
Total 63 
 
Figure 3.14: Length of hospital stay (in days)
  
The median number of days spent in hospital by all in
and ranged from two to 13 
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ay (in days) is shown in Table 3.10 and 
-hospital patients in the table excludes the five deaths 
-hospital patients. 
 
% 
25 
52 
18 
5 
100 
 
-hospital patients was 
days. 
six days 
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3.3.3. Mortality 
Since a total of five deaths were observed out of all the 152 enrolled patients, the 
total mortality rate was 5/152 (3.3%). All the deaths were in in-hospital patients and 
there were no deaths from outpatients; therefore the in-hospital patient mortality rate 
observed was 5/68 (7.4%). 
3.4. CRB-65 performance 
The CRB-65 severity of illness score was applied to all the patients enrolled in the 
study to determine what the decision regarding the site of care would have been if 
the CRB-65 score was the standard criterion used for hospital admission/discharge 
decisions at the Helen Joseph Hospital Emergency Department. 
3.4.1. CRB-65 results 
The results obtained from applying the CRB-65 score to all the 152 enrolled patients 
are given in Table 3.11. 
Table 3.11: CRB-65 score recorded for all the patients in the study 
CRB-65 score Mortality risk Frequency % 
0 Low (1.2%) 107 70% 
 1-2 Intermediate (8.15%) 42 28% 
 3-4 High (31%) 3 2% 
Total   152 100% 
 
Table 3.11 shows that if the CRB-65 score had been applied to all the patients as the 
only criterion for site of care decision by the HJH ED doctors, 107/152 (70.4%) would 
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have had a low mortality risk, implying that they could potentially have been 
managed as outpatients, while 42/152 (27.6%) would have been classified as 
intermediate mortality risk, and they could potentially have been managed as in-
hospital patients together with the remaining 3/152 (2.0%) who would have been 
classified as high mortality risk, implying that they could potentially have been 
suitable for high care or ICU care. 
Table 3.12 shows the cross-tabulation of CRB-65 score and the admission/discharge 
decisions that would have been made if the CRB-65 score was the only criterion 
used by the HJH ED doctors. 
Table 3.12: CRB-65 score by admission/discharge decisions if the CRB-65 score 
was the standard used by the HJH ED doctors 
CRB-65 score Mortality risks Admitted n (%) Discharged n (%) Total 
0 Low (1.2%) _ 107 (100%) 107 
1-2 Intermediate (8.15%) 42 (100%) _ 42 
3-4 High (31%) 3 (100%)  _ 3 
Total  45 (30%) 107 (70%) 152 
Note: row percentages are given in brackets except second column (mortality risks) 
This indicates that if the CRB-65 score was applied as the only criterion for site of 
care decisions by the HJH ED doctors, 107/152 patients (70.4%) would potentially 
have been managed as outpatients, while 45/152 patients (29.6%) would potentially 
have been managed as in-hospital patients. 
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3.4.2. CRB-65 results versus site of care decisions by HJH ED doctors 
Table 3.13 gives a cross-tabulation of the CRB-65 results that would have been 
obtained if the CRB-65 score was the only criterion applied by the HJH ED doctors 
and the actual site of care decisions used by the HJH ED doctors during the study. 
Table 3.13: CRB-65 results and actual admission/discharge decisions by HJH ED 
doctors during the study 
CRB-65 score Mortality risks 
Admitted                    
n (%) 
Discharged               
n (%) Total 
0 Low (1.2%) 34 (32%) 73 (68%) 107 
1-2 Intermediate (8.15%) 31 (74%) 11 (26%) 42 
3-4 High (31%) 3 (100%) _ 3 
Total  68 (45%) 84 (55%) 152 
 Note: row percentages are given in brackets except second column (mortality risks) 
Table 3.13 shows that of the low mortality risk patients, 73/107 (68.2%) were 
managed as outpatients in accordance with the CRB-65 score, but 34/107 (32%) 
were treated as in-hospital patients when they could potentially have been managed 
as outpatients. With regard to these low-risk patients admitted, 25/34 (73%) were 
admitted because of chest radiographic features, 5/34 (15%) were admitted because 
of low oxygen saturation on room air, 2/34 (6%) were admitted because of a CURB-
65 score of 1, 1/34 (3%) was admitted because of a haemodynamic parameter, and 
1/34 (3%) was admitted because of being incorrectly classified as having a CRB-65 
of 1.   
59 
 
With regard to intermediate mortality risk, 11/42 patients (26.2%) were managed as 
outpatients in disagreement with the CRB-65 score and 31/42 (73.8%) were 
managed as in-hospital patients in accordance with the CRB-65 score.  
Regarding the high mortality risk category, no patients were managed as outpatients 
in complete agreement with the CRB-65 score and 3/3 (100%) were managed as in-
hospital patients. These three should have been managed as ICU patients, but none 
of them were actually admitted to the ICU. There was a significant difference 
observed between the site of care decisions by the Helen Joseph Hospital 
Emergency Department doctors and the site of care decisions that would have been 
made if the CRB-65 score was the only criterion applied (p < 0.0001). 
3.4.3. CRB-65 results and time to clinical stability 
Table 3.14 shows a cross-tabulation of the CRB-65 results and the actual time to 
clinical stability observed for the admitted patients. The total of 63 in-hospital patients 
in the table excludes the five deaths that occurred from an overall total of 68 in-
hospital patients. 
Table 3.14: Cross-tabulation of CRB-65 results and time to clinical stability observed 
   Time to clinical stability (days)  
CRB-65 score Mortality risks 1 2 3 Total 
0 Low (1.2%) 16 (47%) 17 (50%) 1 (3%) 34 
1-2 Intermediate (8.15%) 6 (21.5%) 16 (57%) 6 (21.5%) 28 
3-4 High (31%) _ 1 (100%) _ 1 
Total  22 (35%) 34 (54%) 7 (11%) 63 
Note: row percentages are given in brackets except second column (mortality risks) 
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Significant association was observed (p = 0.0069) between time to clinical stability 
observed and the CRB-65 score results that would have been obtained if the CRB-
65 score was used as the only criterion. This indicates that there was a significantly 
shorter time to clinical stability in patients with a lower CRB-65 score. 
3.4.4. CRB-65 results and length of hospital stay 
Table 3.15 shows cross-tabulation of the CRB-65 results and the actual length of 
hospital stay observed for the admitted patients. The total of 63 in-hospital patients in 
the table excludes the five deaths that occurred from an overall total of 68 in-hospital 
patients. 
Table 3.15: Cross-tabulation of CRB-65 results and length of hospital stay observed 
   Length of hospital stay (days)  
CRB-65 score Mortality risks 2 to 4 5 to 7 8 to 10 11 to 13 Total 
0 Low (1.2%) 11 (32%) 15 (44%) 5 (15%) 3 (9%) 34 
1-2 Intermediate (8.15%) 5 (18%) 17 (61%) 6 (21%) _ 28 
3-4 High (31%) _ 1 (100%) _ _ 1 
Total  16 (25%) 33 (52%) 11 (18%) 3 (5%) 63 
Note: row percentages are given in brackets except second column (mortality risks) 
No association was observed (p = 0.5694) between length of hospital stay observed 
and the CRB-65 score results that would have been obtained if the CRB-65 score 
was used as the only criterion. This indicates that there was no tendency to a shorter 
length of hospital stay in patients with a lower CRB-65 score. 
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3.4.5. CRB-65 results and deaths 
Table 3.16 shows a cross-tabulation of deaths observed and the CRB-65 results that 
would have been observed if CRB-65 score was the only criterion used by the HJH 
ED doctors for site of care decisions in relation to the patients. 
Table 3.16: Cross-tabulation of CRB-65 results and deaths observed 
CRB-65 score Mortality risks Alive Dead  Total 
0 Low (1.2%) 107 (100%) _ 107 
1-2 Intermediate (8.15%) 39 (93%) 3 (7%) 42 
3-4 High (31%) 1(33%) 2 (67%) 3 
Total  147 (97%) 5 (3%) 152 
Note: row percentages are given in brackets except second column (mortality risks) 
There were a total of five deaths observed from the in-hospital patients, 3/5 patients 
(60%) would potentially have been classified as intermediate mortality risk and the 
remaining 2/5 patients (40%) as high mortality risk if the CRB-65 score had been the 
only criterion used as the standard for site of care decisions by the Helen Joseph 
Hospital Emergency Department doctors. Patients with a higher CRB-65 score were 
at a significantly higher risk of death compared to patients with a lower CRB-65 
score (p < 0.001). 
 
 
 
 
62 
 
CHAP 4. DISCUSSION AND CONCLUSION 
4.1. Discussion 
This was a prospective, observational, hospital-based study of consecutive cases of 
CAP that presented at Helen Joseph Hospital Emergency Department during the 
period between February 2011 and April 2011. A total of 159 patients, representing a 
diverse spectrum of ethnic groups, were enrolled in the study over the three-month 
period. Seven patients were later excluded because they were subsequently 
confirmed to have pulmonary tuberculosis and therefore 152 patients were included 
in the final analysis.  
4.1.1. Baseline clinical characteristics 
The results have shown that patients were mostly young adults with no difference in 
the gender ratio. There was no difference in age between in-hospital patients and 
outpatients, but more females were managed as in-hospital patients while more 
males were managed as outpatients. 
The overall median age was 36.5 years (Table 3.1), which was similar to the median 
age (42 years) reported by Van Rensburg et al in a previous South African study of 
patients with community-acquired pneumonia in Witbank,43 but lower than the 
median age of 74 years reported by Diez et al, in a Spanish study of serum leptin 
levels in community-acquired pneumonia patients.44 This significant difference in age 
might be explained by the higher prevalence of HIV infection in young adult South 
Africans compared to that in the Spanish population. The youngest patient was 20 
years old and the oldest was 87 years old (Table 3.1). This was similar to the adult 
age range (18 years to 89 years) reported by Van Rensburg et al.43 This also 
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corresponds to the adult age range (18 years to 101 years) reported by Halm et al, in 
a study from New York of time to clinical stability in patients hospitalised with 
community-acquired pneumonia.45 The majority of the patients (92.1%) in the current 
study were less than 65 years of age (Table 3.3). This was higher than the overall 
adult gender distribution by age group (using a cut-off of 65 years) of 56% reported 
by Halm et al.45  
There was no difference in the gender distribution in the patients, with 52% of the 
group being female and 48% male. The gender ratio was therefore 1/1 (Table 3.4). 
This corresponds with the overall adult gender distribution (51% female versus 49% 
male) reported by Halm et al.45 There was no significant difference in gender 
distribution by age group using a cut-off of 65 years (p = 0.646). 
Table 3.1 and Table 3.2 summarise the baseline clinical characteristics of the study 
patients. The majority of patients enrolled in the study had a normal AMTMSAC of 
10/10 (98%). The median systolic BP was 114 mmHg and ranged from 86 mmHg to 
172 mmHg. The overall median diastolic BP was 72 mmHg and ranged from 35 
mmHg to 100 mmHg. The overall median heart rate was 103 beats per minute and 
ranged from 58 beats per minute to 158 beats per minute. The overall median 
respiratory rate was 23.5 breaths per minute and ranged from 14 breaths per minute 
to 38 breaths per minute and the overall median body temperature was 37.8 ºC and 
ranged from 36 ºC to 41 ºC. 
There was no difference (p= 0.985) in the proportion of patients managed as in-
hospital patients (45%) versus outpatients (55%) (Figure 3.9). This was similar to the 
overall site of care distribution (53% outpatients versus 47% in-hospital patients) 
reported by Aujesky et al, in a Swiss study.46 Significantly more females were 
64 
 
managed as in-hospital patients than males (82% versus 18%) (Table 3.5). This was 
in contrast to the percentages reported by Mortensen et al (79% male versus 21% 
female) in an American study of antibiotic therapy and 48-hour mortality in patients 
with pneumonia.47 Conversely, of those treated as outpatients, significantly more 
were males (73%) than females (27%) (Table 3.5). 
There were no significant differences observed in the age distribution (using a cut-off 
of 65 years) between the in-hospital patients and outpatients (p = 0.702). 
4.1.2. Criteria used by the HJH ED doctors to determine the initial site of 
care decision of patients with CAP 
Table 3.8 and Figure 3.12 summarise the criteria used by the HJH ED doctors to 
determine the initial site of care decision of the patients with CAP. There was a 
significant difference in criteria used for admission versus discharge decisions (p < 
0.001) by the HJH ED doctors in that the chest radiograph was used more frequently 
in the decision to admit patients, compared to all other criteria, whereas 
haemodynamic parameters were used more frequently in the decision to discharge 
patients, compared to all other criteria. The specific CXR criteria that encouraged 
HJH ED doctors to admit the patients were not investigated in the current study. 
However the candidate reviewed the CXR of all these patients and noted that the 
most common radiographic features among these patients that were admitted were 
bilateral infiltration, multilobar consolidation and significant pleural effusion. 
As shown in the table the CRB-65 severity of illness score was used infrequently by 
the HJH ED doctors. This study did not address the question why those doctors did 
not frequently use the scoring system. Many ED providers do not follow guideline 
recommendations for the assessment of severity of illness to determine the initial site 
65 
 
of treatment for patients with CAP. Consequently, many low mortality risk patients 
are commonly managed as in-hospital patients and higher mortality risk patients are 
most often managed as outpatients. The study by Aujesky et al found that the most 
commonly reported reasons for admitting low mortality risk patients were the 
presence of a comorbid illness (71%); a laboratory value, vital sign, or symptom that 
preclude ED discharge (29,3%); or a recommendation from a primary care or a 
consulting physician (19.3%). Higher mortality risk patients were most often treated 
as outpatients because of a recommendation by a primary care or consulting 
physician (40%).46 
4.1.3. Outcomes: time to clinical stability, length of hospital stay, and 
mortality   
The overall median time to clinical stability for all in-hospital patients was two days, 
with the range from one day to three days (Table 3.9). This was similar to the overall 
median time to clinical stability (three days for the most lenient definition of stability) 
reported by Halm et al.45 The overall median number of days spent in hospital by all 
in-hospital patients was six days, and ranged from two days to 13 days (Table 3.10). 
This was similar to the overall median length of hospital stay of seven days reported 
by Meijvis et al, in a Dutch study investigating the length of hospital stay in patients 
with community-acquired pneumonia.48 The length of hospital stay of the patients 
was often considerably longer that of the time to clinical stability. There may be many 
reasons for this, such as the need to treat underlying comorbid conditions; however 
the reasons among the patients in the current study were not investigated.  
There was an overall mortality rate of 3.3% (Table 3.16), which was less than the 
overall mortality rate (20%) commonly reported in the literature.4 This was also lower 
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than the overall mortality rate of 20% reported by Nyamande et al, which was a 
previous study from KwaZulu-Natal of adherence to South African CAP antibiotic 
guideline recommendations.4 In that study, the authors demonstrated the poor 
adherence with the South African CAP antibiotic guidelines. Although adherence to 
the RSA guideline recommendations was not addressed in the current study, it is 
possible that greater adherence to the guideline recommendations in the current 
population versus that in the Nyamande study might explain the higher mortality rate 
observed in that area. There were no deaths among the outpatients in the current 
study and none of the higher-risk patients were admitted to ICU. Thus, the in-hospital 
patient mortality rate observed (7.4%) was similar to the in-hospital patients mortality 
rate (5–15%) reported in the literature.5,7,8,45  
4.1.4. CRB-65 results 
If the CRB-65 score had been applied to all the patients as the only criterion for site 
of care decision by the HJH ED doctors, 70% of the patients would have had a low 
mortality risk, implying that they could potentially have been managed as outpatients, 
while 28% would have been classified as intermediate mortality risk, indicating that 
they could potentially have been managed as in-hospital patients together with the 
remaining 2.0% who would have been classified as high mortality risk, implying that 
they could potentially have been suitable for high care or ICU care (Table 3.11). This 
distribution of patients was different from the overall patient percentages (52% low 
mortality risk, 34% intermediate mortality risk, and 14% high mortality risk) reported 
by Mortensen at al.49 This was also different from the overall site of care percentage 
(53% outpatients versus 47% in-hospital patients) reported by Aujesky et al.46  
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This study shows that of the low mortality risk patients, 68.2% were managed as 
outpatients in accordance with the CRB-65 score, but 32% were treated as in-
hospital patients when they could potentially have been managed as outpatients 
(Table 3.13). This was similar to the overall percentage (37.4%) of low-risk patients 
managed as in-hospital patients reported by Aujesky et al46, but was considerably 
lower than the overall percentage (52%) reported by Mortensen et al.47 With regard 
to intermediate mortality risk, 26% of these patients were managed as outpatients in 
disagreement with the CRB-65 score and 74% were managed as in-hospital patients 
in accordance with the CRB-65 score (Table 3.13). Regarding the high mortality risk 
category, no patients were managed as outpatients in complete agreement with the 
CRB-65 score, and all of them were managed as in-hospital patients (Table 3.13). 
This was different to the overall percentage (20%) of higher mortality risk patients 
treated as outpatients reported by Aujesky et al.46 In that study the authors 
demonstrated that higher-risk patients were most often treated as outpatients 
because of a recommendation by a primary care or consulting physician (40%).46 
There was thus a significant disagreement observed between the site of care 
decisions by the Helen Joseph Hospital Emergency Department doctors and the site 
of care decisions that would have been made if the CRB-65 score was the only 
criterion applied (p < 0.0001). 
4.1.5. CRB-65 performance 
4.1.5.1. CRB-65 score and time to clinical stability 
There was a significantly shorter time to clinical stability in patients with a lower 
CRB-65 score (p = 0.0069) (Table 3.14). Thus, this study demonstrates the ability of 
the CRB-65 to accurately predict time to clinical stability for CAP hospitalised 
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patients. The study by Arnold et al also found that the CRB-65 score had a good 
accuracy for predicting time to clinical stability in hospitalised patients with CAP.49 In 
addition to this, the authors demonstrated that the predictive accuracy of the CRB-65 
score was equivalent to that of the PSI (0.647, 95%CI: 0.619-0.6700 versus 0.638, 
95%CI: 0.613-0.660) for determining time to clinical stability.49 
4.1.5.2. CRB-65 score and length of hospital stay 
There was no tendency to a shorter length of hospital stay in patients with a lower 
CRB-65 score in the current study (p = 0.5694) (Table 3.15). The study by Zuberi et 
al, which was a prospective comparison of prediction rules of mortality risk for 
community-acquired pneumonia in a developing country, also found that the length 
of hospital stay did not increase with a higher CRB-65 score.50 This was in contrast 
with the study by Ewig et al on new perspectives on community-acquired pneumonia 
in 388 406 patients, which concluded that the length of hospital stay was associated 
with the severity of the disease (mean (SD) length of hospital stay 9.45 (7.82) versus 
12.39 (8.47) versus 14.5 (10.69), respectively for risk class 1-3, excluding death).51 
4.1.5.3. CRB-65 score and death 
There were a total of five deaths observed from the in-hospital patients of which 
three would have been classified as having intermediate mortality risk and the 
remaining two as having a high mortality risk if the CRB-65 score had been the only 
criterion used as the standard for site of care decisions by the Helen Joseph Hospital 
Emergency Department doctors (Table 3.16). This study shows that patients with a 
higher CRB-65 score are at a significantly higher risk of death than patients with a 
lower CRB-65 score (p < 0.001). The study by Ewig et al found that the CRB-65 
score accurately predicted death in the three class pattern.51 The study by Chalmers 
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et al also found that the CRB-65 score had a good accuracy for predicting mortality 
in hospitalised patients with CAP.52 In addition to this finding, the authors of that 
study also demonstrated that all the three severity of illness scores, namely the PSI, 
the CURB-65 and the CRB-65, had an equivalent 30-day mortality predictive 
accuracy (p= 0.09) for patients hospitalised with CAP.52  
4.1.5.4. CRB-65 score and initial site of care for patients with CAP 
No deaths were observed among the outpatients and all the deaths occurred among 
patients that were admitted to Helen Joseph Hospital. There were a total of five 
deaths observed of which all would potentially have been managed as in-hospital 
patients (with even two admissions, at least, to ICU) if the CRB-65 score had been 
the only criterion used as the standard for site of care decisions by the HJH ED 
doctors (Table 3.16). The ability of the CRB-65 score to accurately predict both the 
time to clinical stability for CAP hospitalised patients (Table 3.14) and the risk of 
deaths associated (Table 3.16) demonstrate that the CRB-65 severity of illness 
score performed well in its ability to determine the initial site of care for patients with 
CAP.  
4.1.6. Potential limitations of this study 
The study does have a few potential limitations. The study was undertaken at one 
site, in one area of the country and in a public hospital setting only. As such the 
findings may not be generalisable to other geographical areas of South Africa or to 
other settings, such as the private sector.  
Furthermore, the ethnic origin of the patients, their socio-economic status or home 
circumstances, and their habits (e.g. excessive alcohol consumption, drug use, or 
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cigarette smoking) were not recorded or used for any analysis, and it is possible that 
these factors may have impacted on the findings.  
 
4.1.7. Potential strengths of this study 
The study does have a number of strengths. In the first instance it was a prospective 
study and therefore there was the opportunity to collect all the information that was 
required for the study analysis. The study was powered, with the help of a 
statistician, prior to being conducted, to ensure that a sufficient number of patients 
was recruited in order to allow accurate statistical analysis. This study is also the first 
study attempting to validate the CRB-65 score, or in fact any severity of illness 
scoring system for CAP patients in the South African environment.    
4.2. Conclusion 
The study shows that chest radiograph was the commonest criterion used by the 
Helen Joseph Hospital Emergency Department doctors to determine the need for 
admission of the patients with CAP, while the haemodynamic parameters were the 
commonest criteria used for discharge decision. The CRB-65 score was infrequently 
used in current practice by the Helen Joseph Hospital Emergency Department 
doctors for admitting or discharging CAP patients. This study demonstrates the 
ability of the CRB-65 severity of illness score to accurately predict both the time to 
clinical stability for patients hospitalised with CAP and the risk of death associated. In 
addition, this study demonstrates that the CRB-65 severity of illness score performed 
well in its ability to determine the initial site of care for patients with CAP at the Helen 
Joseph Hospital. Thus, this scoring system may be a valuable tool to consider in 
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decision making regarding the initial site of care of patients with CAP presenting to 
an emergency department. 
It remains important to remember that severity of illness assessment in CAP is an 
“Art of Medicine” decision. Severity of illness scores are useful to assist in the 
assessment of severity of illness, but they cannot be used alone for decisions 
regarding severity of illness or site of care. They need to be supplemented by the 
individual experience and/or expertise of the attending clinician. While many of the 
scoring systems have individual strengths they also have weaknesses and none of 
them take into account factors such as social circumstances, excessive use of 
alcohol, likely adherence to medication, presence of dementia, and various other 
factors that may impact negatively on the outcome of patients with CAP, irrespective 
of the potential severity of the infection.  
4.3. Recommendations for further studies 
It would seem, based on the current investigation, that further studies with the CRB-
65 score would be useful, particularly in our setting in South Africa. For example, one 
may consider doing an interventional study, such as educating the ED staff about the 
CRB-65 severity of illness score and then instituting a program in which the CRB-65 
score becomes part of the assessment of initial site of care for patients with CAP and 
evaluating its performance and potential benefits.   
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Appendix A: Pneumonia Severity Index3  
 
 
 
Demographic factors  
Age (in years)  
Men  
Women -10 
Nursing home resident  +10 
 
 
Coexisting illnesses  
Neoplastic disease  +30 
Liver disease  +20 
Congestive heart failure  +10 
Cerebrovascular disease  +10 
Renal disease  +10 
 
Findings on physical examination 
Altered mental status  +20 
Respiratory rate ≥ 30/min  +20 
SBP <90 mm Hg  +20 
Temperature <35ºC or ≥ 40ºC  +15 
Pulse ≥ 125 beats/min  +10 
 
Laboratory and radiographic 
findings 
Arterial pH <7.35  +30 
Urea ≥ 30/mg/dl (11 mmol/l)  +20 
Sodium < 130 mmol/l  +20 
Glucose ≥ 250 mg/dl (14 
mmol/l)  
+10 
Hematocrit <30%  +10 
PaO2 < 60 mm Hg or oxygen 
saturation < 90%  
+10 
Pleural effusion  +10 
 
    
                                                       Stratification of risk score 
 
 
Risk 
 
Risk Class  
 
Score 
 
Mortality 
  
 
Low 
 
I 
 
Based on algorithm  
 
0.1% Outpatient 
treatment Low II ≤ 70 0.6% 
Low III 71-90 0.9% 
Moderate IV 91-130 9.3% Hospital 
admission High V >130 27.0% 
 
 
 
* Interactive tool from the Assessment of the Variation and Outcomes of Pneumonia 
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Appendix B: Early Goal-Directed Therapy protocol for sepsis28 
 
 
 
 
 
 
 
 
 Appendix C: Algorithm for the management of CAP in 
South Africa9
74 
adults in 
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Appendix D: Recommended dosages of antibiotics for CAP3 
Penicillins Fluroquinolones 
  
Oral 
Amoxycillin: 1 g eight-hourly 
Amoxycillin-clavulanate: minimum of 500 mg amoxicillin with 
125 mg clavulanate eight-hourly. Sustained release 
preparations allow for 1 g 12-hourly dosing. 
Oral 
Gemifloxacin: 320 mg daily 
Levofloxacin: 500 mg 12-hourly or 750 mg daily 
Moxifloxacin: 400 mg daily 
Parenteral 
Penicillin G: 2-4 million units six-hourly 
Ampicillin or Amoxycillin: 1-2 g six-hourly 
Amoxycillin-clavulanate: 1,2 g eight-hourly 
Parenteral 
Levofloxacin: 500 mg 12-hourly or 750 mg daily 
Moxifloxacin: 400 mg daily 
Cephalosporins Aminoglycosides 
  
Oral 
Second generation 
Cefuroxime axetil: 750 mg – 1 gm 12-hourly 
Cefpodoxime: 400 mg 12-hourly  
Parenteral 
Second generation 
Cefuroxime: 1,5 g eight-hourly 
Third generation 
Ceftriaxone: 2 g daily (can increase to 2 g 12-hourly) 
Cefotaxime: 3–4 g daily in two–four divided doses 
Parenteral 
Amikacin: 15 mg/kg/day (maximum 1,5 g daily) 
gentamicin: 5–7 mg/kg/day (usual 320 mg daily) 
Tobramycin: 5–7 mg/kg/day (usual 320 mg daily) 
Macrolide/azalides Tetracyclines 
Oral 
Erythromycin: 500 mg six-hourly 
Clarithromycin: 500 mg 12-hourly 
Clarithromycin XL: 1g daily 
Azithromycin: 500 mg daily 
Parenteral 
Erythromycin: 4–5 mg/kg six-hourly given into a large vein 
Clarithromycin: 500 mg 12-hourly 
Azithromycin: 500 mg daily 
Oral 
Doxycycline: 200 mg stat followed by 100 mg 12-hourly  
Ketolides 
 
Oral 
Telithromycin: 800 mg daily 
 
 
 
76 
 
Appendix E: Ethics clearance certificate 
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Appendix F: HJH ED doctor information sheet  
Dear Staff 
Good day! I am Doctor Kabundji Dalton – I am currently a student in the MSc Med 
Emergency Medicine at the Division of Emergency Medicine, Faculty of Heath 
Sciences, University of the Witwatersrand and I am doing a project for my research 
report.  
This study is being conducted by me in partial fulfilment of the requirements for the 
MSc Med EM degree. 
The aim of the study is to assess the severity of illness in patients with community-
acquired pneumonia and for decisions regarding whether these patients need 
admission to hospital or could be safely discharged home. 
I will also be determining what criteria are used by the Helen Joseph Hospital 
emergency department doctors for admitting or discharging community-acquired 
pneumonia patients.  
I would like to invite you to help me with the study. Please would you call me when 
you have completed the evaluation of a patient with Community-Acquired 
Pneumonia? I will then proceed as follows: 
• I will confirm that the patient fulfils the study’s inclusion criteria by asking 
him/her questions about his/her conditions and details about his or her 
symptoms. I will also check his/her chest radiograph.  
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• Following this, I will ascertain from you on what basis you decided to either 
admit the patient to hospital or to discharge him/her home. All reasons given 
will be recorded. 
• I will assess the severity of the patient‘s illness.  
• In order to protect patient’s confidentiality, when recording details, patient will 
be given a unique patient identification number (PIN). The PIN will be known 
only to the researcher. 
• I will follow the progress of the patient illness.  
• Once I have collected all the data, I will analyse it to compare the outcomes of 
the patient based on the clinical decisions versus the severity score 
recommendations.  
I will not record any of your details for this study. 
       Thanks 
DM Kabundji 
Date:                                                                                                 CAP/CRB-65 
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Appendix G: Patient information sheet and consent form 
Dear Sir/Madam 
Good day! I am Doctor Kabundji Dalton – I am currently a student in the MSc Med 
Emergency Medicine at the Division of Emergency Medicine, Faculty of Heath 
Sciences, University of the Witwatersrand. I am inviting you to volunteer for a 
research study. 
This study is being conducted by me in partial fulfilment of the requirements for the 
MSc Med EM degree. 
The aim of the study is to determine the value of using the CRB-65 score in 
assessing the severity of illness in patients with pneumonia and for decisions 
regarding whether these patients need admission to hospital or could be safely 
discharged home. 
The CRB-65 scoring system is a well-known scoring system used to assess patients 
with pneumonia. I will also be determining what criteria are used by the Helen 
Joseph Hospital emergency department doctors for admitting or discharging 
community-acquired pneumonia patients.  
Please understand that your decision to participate in this research study is entirely 
voluntary and you are free to decline to join or withdraw your consent at any time, 
without consequence. If you agree I will proceed as follow: 
• I will confirm that you fulfil the study’s inclusion criteria by asking you 
questions about your condition and details about your symptoms. I will also 
check your chest x-ray.  
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• Following this, I will ascertain from my colleague (your doctor) on what basis 
they decided to either admit you to hospital or to discharge you home. All 
reasons given will be recorded. 
• I will assess the severity of your illness using the CRB-65 score.  
• In order to protect your confidentiality, when recording your details you will be 
given a unique patient identification number (PIN). The PIN will be known only 
to the researcher. 
• I will follow the progress of your illness. If you are discharged home, would 
you please supply me with a contact number, which will be kept confidential, 
to contact you as to know how well you have done? If you are to be admitted 
to hospital, I will follow the course of your stay until you leave the hospital.  
• Once I have collected all the data, I will analyse it to compare the CRB-65 
severity of illness score and outcomes with the HJH ED doctors’ criteria. 
• I will need you to sign consent at the outset, and will retain a signed copy. Any 
personal information of yours that I collect during the course of this study will 
be kept strictly confidential. 
I,                                                                                (participant), fully understand the 
research study aim, that my participation is entirely voluntary and I may withdraw 
from the study at any time, without any consequences. 
Patient’s signature:  
I,                                                      (the researcher), confirm that I have explained 
the research process to participant, and that I will adhere to the generally accepted 
ethical norms of research. 
Researcher’s signature:                                   Witness’s signature:   
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Date:      /   /2010. 
PIN: _________                                                                               CAP/CRB-65 
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Appendix H: Family’s information and consent form 
Dear Sir/Madam 
Good day! I am Doctor Kabundji Dalton – I am currently a student in the MSc Med 
Emergency Medicine at the Division of Emergency Medicine, Faculty of Heath 
Sciences, University of the Witwatersrand. I am inviting you to give permission for 
your relative to participate in a research study. 
This study is being conducted by me in partial fulfilment of the requirements for the 
MSc Med EM degree. 
The aim of the study is to determine the value of using the CRB-65 score in 
assessing the severity of illness in patients with pneumonia and for decisions 
regarding whether these patients need admission to hospital or could be safely 
discharged home.  
The CRB-65 scoring system is a well-known scoring system used to assess patients 
with pneumonia. I will also be determining what criteria are used by the Helen 
Joseph Hospital emergency department doctors for admitting or discharging 
community-acquired pneumonia patients.  
Please understand that the decision for you to allow your relative to participate in this 
research study is entirely voluntary and you are free to decline or to withdraw 
consent at any time, without consequences. If you agree I will proceed as follow: 
• I will confirm that the case fits the study’s inclusion criteria by asking 
questions about your relative’s condition and details about symptoms and 
signs of his or her current illness. I will also check his or her chest x-ray.  
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• Following this, I will ascertain from my colleague (your relative’s doctor) on 
what basis they decided to admit your relative to hospital or to discharge the 
patient home. All reasons given will be recorded. 
• I will assess the severity of illness of your relative using the CRB-65 score. In 
order to protect the confidentiality of the patient, each patient will be given a 
unique patient identification number (PIN). The PIN will be known only to the 
researcher. 
• I will follow the progress of the patients. If discharged home, with your 
permission I would please like to get a contact number, which will be kept 
confidential, in order to contact the patient in order to determine how well he 
or she did. For those admitted to hospital, I will follow the case until they leave 
the hospital. 
• Once all the data is collected I will analyse it to compare the CRB-65 severity 
of illness score and outcomes with the HJH ED doctors’ criteria. 
I will need you to sign consent on his or her behalf at the outset, and will retain a 
signed copy. I will keep all personal information collected during the course of this 
study strictly confidential. 
I                                                                                (Family member), fully 
understand the research study aim, that my relative’s participation is entirely 
voluntary and that I may withdraw my relative from the study at any time, without any 
consequences. I accept to sign this consent form on his or her behalf. 
Patient’s relative signature:        
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I,                                                      (the researcher), confirm that I have explained 
the research process to participant, and that I will adhere to the generally accepted 
ethical norms of research. 
Researcher’s signature:                                      Witness’s signature: 
Date:      /   /2010. 
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Appendix I: Retrospective patient information and consent form 
Dear Sir/Madam 
Good day! I am Doctor Kabundji Dalton – I am currently a student in the MSc Med 
Emergency Medicine at the Division of Emergency Medicine, Faculty of Heath 
Sciences, University of the Witwatersrand.  
I am doing a research study in partial fulfilment of the requirements for the MSc Med 
EM degree.   
When you were very ill, with your relative’s permission I included you in this study. I 
would now like to request your permission to include your information in my study.  
The aim of the study is to determine the value of using the CRB-65 score in 
assessing the severity of illness in patients with pneumonia and for decisions 
regarding whether these patients need admission to hospital or could be safely 
discharged home.  
The CRB-65 scoring system is a well-known scoring system used to assess patients 
with pneumonia. I will also be determining what criteria are used by the Helen 
Joseph Hospital emergency department doctors for admitting or discharging 
community-acquired pneumonia patients.  
The procedures followed for this study are as follows: 
• I confirm that the case fits the study’s inclusion criteria and check the chest x-
ray.  
• I ascertain from my ED colleague doctor on what basis they decided to admit 
you to hospital. All reasons given are recorded. 
86 
 
• I then objectively assess the severity of illness using the CRB-65 score. In 
order to protect your confidentiality, I gave you a unique patient identification 
number (PIN). The PIN is known only to me. 
Currently I would like to follow the progress of your illness until you are discharged 
from hospital. I will determine your length of your hospital/high-care/ICU stay, and 
the time it takes for your symptoms to stabilise.  
Once the information from all the patients is collected I will then analyse the ability of 
the CRB-65 to accurately predict severity of illness and outcome.  
If you agree, you will need to sign a consent form allowing me to continue collecting 
data from you and will retain a signed copy. I will keep all your information strictly 
confidential. 
I                                                                                (participant), fully understand the 
research study aim, that my participation is entirely voluntary and I may withdraw 
from the study at any time, without any consequences. 
Patient’s signature:             
I,                                                      (the researcher), confirm that I have explained 
the research process to participant, and that I will adhere to the generally accepted 
ethical norms of research. 
Researcher’s signature:                                        Witness’s signature: 
Date:      /   /2011. 
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Appendix J: Patient identification sheet 
1. Surname and initials: 
2. Sex: 
3. Age: 
4. Cell number or relative’s cell number: 
5. PIN: 
6. Researcher:  
 
 
Dalton Kabundji 
Date:      /  /2011                                Signature: 
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Appendix K: Study questionnaire and case report form 
Question to ED doctor:  
1. Where have you decided to treat the patient? (Tick if present)  
 
Outpatient treatment  
Inpatient treatment  
 
2. On what basis have you decided to admit the patient to hospital or to 
discharge the patient home?  
Reasons given (Tick if present) 
1. Confusion 
2. SBP < 90 or DBP ≤ 60 mmHg 
3. RR ≥30/min 
4. Blood urea >7mmol/l 
5. CXR-confirmed pneumonia 
6. Associated co-morbidity (specify) 
7. Need for IV antibiotics 
8. No need for IV antibiotics 
9. Need for IV fluids 
10. Presence of temperature ≥380C 
11. Patient wasted 
12. Patient unable to eat, drink or walk 
13. Patient needs intubation and/or is mechanically  ventilated 
14. Patient need vasopressors support 
15. Aged above 65 years 
16. Aged below 65 years 
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17. Patient refused to be admitted 
18. Poor socioeconomic status 
 
19. Other reasons 
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Gender:  M / F                                                                       Age:  
Date of evaluation  
 Day  Day  Day  Day  Day  Day  
Altered breath 
sounds/consolidation 
      
Fever or hypothermia       
Rigors       
Sweats       
Cough       
Sputum production       
Pleuritic chest pain       
Cyanosis       
Shortness of breath       
Rapid respiratory rate        
Temperature       
Pulse rate       
Partial pressure of arterial  
O2  
      
CRB-65 
Confusion       
Respiratory rate ≥ 30 
breaths/min  
      
Blood pressure (SBP < 90 
mmHg, DBP ≤ 60 mmHg)  
      
Age ≥ 65 years   
Total CRB-65 score  
Chest radiograph 
Confirmation of pneumonia 
Description 
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Researcher’ signature:    
 
Drawing of the CXR 
 
 
 
 
 
 
 
Patient Outcome 
Patient lived  
Patient died  
Date of death  
Medical ward management  
High care management  
ICU admission  
Date of discharge from 
hospital 
 
Outpatient management  
Date of resolution of 
symptoms/signs (time to 
clinical stability) 
 
Length of medical ward 
stay 
 
Length of ICU stay  
Date of patient step-down  
Length of hospitalisation prior 
to step-down 
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